Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 153

Sort by

Sort Order Select

Journal Articles

Resource Utilization and Factors Prolonging Hospitalization for Patients with Relapsed and Refractory Large B-Cell Lymphoma Receiving Tisagenlecleucel Versus Axicabtagene Ciloleucel

Agrima Mian, MBBS, MD, Wei Wei, MS, Brian T. Hill, MD, Betty K. Hamilton, MD, Allison M. Winter, MD, Jack Khouri, MD, Brad Pohlman, MD, Deepa Jagadeesh, MDMPH, Alex V. Mejia Garcia, MD, Faiz Anwer, MD, Aaron T. Gerds, MDMS, Matt Kalaycio, MD, Robert M. Dean, MD, Ronald Sobecks, MD, Navneet S. Majhail, MD MS

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-137801

Published: 2020

Journal Articles

Hematopoietic Progenitor Cell Mobilization and Collection for Autologous Hematopoietic Cell Transplantation in AL Amyloidosis: A Single Center Experience

Anne K Hubben, MD, Lisa Rybicki, MS, Kristin Ricci, MD, Navneet S. Majhail, MD MS, Matt Kalaycio, MD, Betty K. Hamilton, MD, Brian T. Hill, MD, Allison M. Winter, MD, Brad Pohlman, MD, Deepa Jagadeesh, MDMPH, Faiz Anwer, MD, Robert M. Dean, MD, Ronald Sobecks, MD, Chakra P Chaulagain, MD, Hien D. Liu, MD, Jack Khouri, MD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-140456

Published: 2020

Journal Articles

Younger HLA-Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (allo-HCT) for Myelodysplastic Syndromes (MDS) Is Associated with Superior Disease-Free Survival Compared to Older HLA-Identical Sibling Donors: CIBMTR Analysis

Guru Subramanian Guru Murthy, MD, Soyoung Kim, Zhen-Huan Hu, MPH, Noel Estrada-Merly, MS, Ryotaro Nakamura, MD, Betul Oran, MDMS, Bart L. Scott, MD, Ronald Sobecks, MD, Wael Saber, MD MS

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-140647

Published: 2020

Journal Articles

Comparison of Outcomes and Quality-of-Life Measures Following Haploidentical Vs. Matched Related/Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Sanghee Hong, MD, Lisa Rybicki, MS, Linda McLellan, LISW, Jane Dabney, LISW-S, Aaron T. Gerds, MDMS, Seth J Rotz, MD, Matt Kalaycio, MD, Rabi Hanna, MD, Betty K. Hamilton, MD, Navneet S. Majhail, MD MS, Ronald Sobecks, MD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-138939

Published: 2020

Journal Articles

Feedback Responses of the Pyrimidine Metabolism Network Mediate Resistance to Decitabine and 5-Azacytidine

Xiaorong Gu, PhD, Rita Tohme, PhD, Benjamin K. Tomlinson, MD, Lisa Durkin, Caroline Schuerger, Asmaa M Zidan, MB, BCh, Tomas Radivoyevitch, PhD, Hetty E. Carraway, MD MBA, Ronald Sobecks, MD, Betty K. Hamilton, MD, Alan Lichtin, MD, Jaroslaw P. Maciejewski, MD PhD, Yogenthiran Saunthararajah, MD

Blood (2019) 134 (Supplement_1): 537.

https://doi.org/10.1182/blood-2019-125823

Published: 2019

Journal Articles

Inotuzumab Ozogamicin Post-Transplant for Acute Lymphocytic Leukemia

Leland Metheny, III, MD, Ronald Sobecks, MD, Benjamin K. Tomlinson, MD, Folashade Otegbeye, MBBChir,MPH, Brenda Cooper, MD, Navneet S. Majhail, MD MS, Paolo Caimi, MD, Kirsten M Boughan, DO, Molly M Gallogly, MD PhD, Ehsan Malek, MD, Erin Galloway, RN BSN, Betty K. Hamilton, MD, Matt Kalaycio, MD, Aaron T. Gerds, MD MS, Marcos de Lima, MD

Blood (2019) 134 (Supplement_1): 1948.

https://doi.org/10.1182/blood-2019-125940

Published: 2019

Journal Articles

Identifying Factors That Predict for Unplanned Readmissions for Acute Myeloid Leukemia Patients Receiving Consolidation Cytarabine Based Therapies

Caitlin Siebenaller, PharmD, Madeline Waldron, PharmD, BCOP, Kelly Gaffney, PharmD, Brian P. Hobbs, PhD, Ran Zhao, Marc Earl, PharmD, Marina Feldman, PharmD, BCCCP, Hetty E. Carraway, MD MBA, Anjali S. Advani, MD, Aziz Nazha, MD, Aaron T. Gerds, MD MS, Bhumika J. Patel, MD, Betty K. Hamilton, MD, Ronald Sobecks, MD, Matt Kalaycio, MD, Mikkael A. Sekeres, MD MS, Sudipto Mukherjee, MD PhD MPH

Blood (2019) 134 (Supplement_1): 3433.

https://doi.org/10.1182/blood-2019-128807

Published: 2019

Journal Articles

Long-Term Experience with Large Granular Lymphocytic Leukemia Evolving after Solid Organ and Hematopoietic Stem Cell Transplantation

Hassan Awada, Reda Z. Mahfouz, MD PhD, Jibran Durrani, Ashwin Kishtagari, MBBS, Deepa Jagadeesh, MDMPH, Alan Lichtin, MD, Brian T. Hill, MD, Betty K. Hamilton, MD, Hetty E. Carraway, MD MBA, Navneet S. Majhail, MD MS, Ronald Sobecks, MD, Valeria Visconte, PhD, Matt Kalaycio, MD, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 1226.

https://doi.org/10.1182/blood-2019-130167

Published: 2019

Journal Articles

Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Flurabine Improves Transplant Outcomes in Older MDS Patients

Betul Oran, MDMS, Kwang Woo Ahn, PhD, Caitrin Fretham, Mithun Vinod Shah, MD PhD, Ryotaro Nakamura, MD, Bart L. Scott, MD, Ronald Sobecks, MD, Uday Popat, MD, Wael Saber, MD MS

Blood (2019) 134 (Supplement_1): 253.

https://doi.org/10.1182/blood-2019-121970

Published: 2019

Journal Articles

Targeted Treatment and Survival Following Relapse after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia and MDS in the Contemporary Era

Sanghee Hong, MD, Lisa Rybicki, MS, Donna Corrigan, Betty K. Hamilton, MD, Ronald Sobecks, MD, Matt Kalaycio, MD, Robert M. Dean, MD, Brian T. Hill, MD, Brad Pohlman, MD, Deepa Jagadeesh, MDMPH, Faiz Anwer, MD, Navneet S. Majhail, MD MS

Blood (2019) 134 (Supplement_1): 4567.

https://doi.org/10.1182/blood-2019-124533

Published: 2019

Journal Articles

Interactions between Donor Activating Killer Immunoglobulin-like Receptors (KIRs) and Somatic Mutations and Their Association with Outcomes after Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia (AML)

Blood (2019) 134 (Supplement_1): 4599.

https://doi.org/10.1182/blood-2019-131011

Published: 2019

Journal Articles

Outcomes and Factors Impacting Use of Axicabtagene Ciloleucel in Refractory and Relapsed Large B-Cell Lymphoma: An Intent-to-Treat Analysis

Agrima Mian, MBBS, MD, Wei Wei, MS, Allison M. Winter, MD, Jack Khouri, MD, Deepa Jagadeesh, MDMPH, Faiz Anwer, MD, Aaron T. Gerds, MD MS, Robert M. Dean, MD, Ronald Sobecks, MD, Brad Pohlman, MD, Matt Kalaycio, MD, Betty K. Hamilton, MD, Navneet S. Majhail, MD MS, Brian T. Hill, MD

Blood (2019) 134 (Supplement_1): 4452.

https://doi.org/10.1182/blood-2019-127087

Published: 2019

Journal Articles

A Phase I Trial of Venetoclax in Combination with BEAM Conditioning Chemotherapy (V-BEAM) with Autologous Stem Cell Transplantation in Non-Hodgkin Lymphoma

Allison M. Winter, MD, Kirsten M Boughan, DO, Jack Khouri, MD, Paolo Caimi, MD, Faiz Anwer, MD, Brenda Cooper, MD, Deepa Jagadeesh, MDMPH, Robert M. Dean, MD, Aaron T. Gerds, MD MS, Ronald Sobecks, MD, Brad Pohlman, MD, Matt Kalaycio, MD, Betty K. Hamilton, MD, Marcos de Lima, MD, Navneet S. Majhail, MD MS, Brian T. Hill, MD

Blood (2019) 134 (Supplement_1): 5705.

https://doi.org/10.1182/blood-2019-124602

Published: 2019

Journal Articles

Pattern of Somatic Mutation Changes from Diagnosis to Relapse Following Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Sanghee Hong, MD, Cassandra M Kerr, MS, Lisa Rybicki, MS, Valeria Visconte, PhD, Jibran Durrani, Hassan Awada, MD, Betty K. Hamilton, MD, Ronald Sobecks, MD, Matt Kalaycio, MD, Aaron T. Gerds, MD MS, Mikkael A. Sekeres, MD MS, Hetty E. Carraway, MD MBA, Sudipto Mukherjee, MD PhD MPH, Anjali S. Advani, MD, Aziz Nazha, MD, Navneet S. Majhail, MD MS, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 2716.

https://doi.org/10.1182/blood-2019-130352

Published: 2019

Journal Articles

Psychosocial Evaluation in Allogeneic Hematopoietic Cell Transplantation Recipients (Allo HCT): Psychosocial Assessment of Candidates for Transplant (PACT) As a Tool to Identify High-Risk Patients and Its Association with Transplant Outcomes

Sanghee Hong, Lisa Rybicki, MS, Jane Dabney, LISW-S, Christine Lawrence, LISW-S, Betty K. Hamilton, MD, Matt Kalaycio, MD, Linda McLellan, LISW, Ronald Sobecks, MD, Stephanie J. Lee, MD MPH, Navneet S. Majhail, MD MS

Blood (2018) 132 (Supplement 1): 3600.

https://doi.org/10.1182/blood-2018-99-114172

Published: 2018

Journal Articles

Tyrosine Kinase Inhibitors with or without Donor Lymphocyte Infusion Continue to Provide Long-Term Survival after Relapse of Chronic Myeloid Leukemia Following Hematopoietic Cell Transplantation

Sarah Ann Schmidt, PharmD, Jennifer Holter Chakrabarty, MD, Ying Liu, PhD, Zhen-Huan Hu, MPH, Kirsten M. Williams, MD, Edwin P. Alyea, III, MD, Uday Popat, MD, Ronald Sobecks, MD, Bart L Scott, MD, Wael Saber, MD MS

Blood (2018) 132 (Supplement 1): 704.

https://doi.org/10.1182/blood-2018-99-118918

Published: 2018

Journal Articles

Pharmacist Interventions on Outpatient Leukemia Patients Improve Safety

Madeline Waldron, PharmD, Caitlin Siebenaller, PharmD, Marc Earl, PharmD, Hetty E. Carraway, MD MBA, Anjali S. Advani, MD, Aziz Nazha, Aaron T. Gerds, MDMS, Betty K. Hamilton, MD, Ronald Sobecks, MD, Matt Kalaycio, MD, Barb Tripp, CNS, Brian P. Hobbs, PhD, Sudipto Mukherjee, MD PhD MPH, Mikkael A. Sekeres, MD MS

Blood (2018) 132 (Supplement 1): 712.

https://doi.org/10.1182/blood-2018-99-110029

Published: 2018

Journal Articles

Survival Advantage to Allogeneic Transplant in Patients with Myelofibrosis with Intermediate-1 or Higher DIPSS Score

Blood (2018) 132 (Supplement 1): 4288.

https://doi.org/10.1182/blood-2018-99-119002

Published: 2018

Journal Articles

Risk of Venous Thromboembolism in Acute Leukemias: A Meta-Analysis

Madeline Waldron, PharmD, Caitlin Siebenaller, PharmD, Brian P. Hobbs, PhD, Marc Earl, PharmD, Mary Schleicher, Hetty E. Carraway, MD MBA, Anjali S. Advani, MD, Aziz Nazha, Aaron T. Gerds, MD MS, Betty K. Hamilton, MD, Ronald Sobecks, MD, Matt Kalaycio, MD, Mikkael A. Sekeres, MD MS, Sudipto Mukherjee, MD PhD MPH

Blood (2018) 132 (Supplement 1): 4805.

https://doi.org/10.1182/blood-2018-99-115256

Published: 2018

Journal Articles

Adolescent and Young Adult (AYA) Hematopoietic Cell Transplantation (HCT) Recipients Have Similar Quality of Life (QoL) Compared to Older Adults in the First Year Post-Transplantation

Reema R Mathanda, MD, Betty K. Hamilton, MD, Lisa Rybicki, MS, Anjali S. Advani, MD, Brian J. Bolwell, MD, Amy Colver, LISW, Jane Dabney, LISW-S, Christina Ferraro, CNP, Aron Flagg, MD, Rabi Hanna, MD, Matt Kalaycio, MD, Christine Lawrence, LISW-S, Linda McLellan, LISW, Ronald Sobecks, MD, Navneet S. Majhail, MD MS

Blood (2018) 132 (Supplement 1): 4768.

https://doi.org/10.1182/blood-2018-99-113027

Published: 2018

NARROW

Resource Utilization and Factors Prolonging Hospitalization for Patients with Relapsed and Refractory Large B-Cell Lymphoma Receiving Tisagenlecleucel Versus Axicabtagene Ciloleucel

Hematopoietic Progenitor Cell Mobilization and Collection for Autologous Hematopoietic Cell Transplantation in AL Amyloidosis: A Single Center Experience

Younger HLA-Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (allo-HCT) for Myelodysplastic Syndromes (MDS) Is Associated with Superior Disease-Free Survival Compared to Older HLA-Identical Sibling Donors: CIBMTR Analysis

Comparison of Outcomes and Quality-of-Life Measures Following Haploidentical Vs. Matched Related/Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Feedback Responses of the Pyrimidine Metabolism Network Mediate Resistance to Decitabine and 5-Azacytidine

Inotuzumab Ozogamicin Post-Transplant for Acute Lymphocytic Leukemia

Identifying Factors That Predict for Unplanned Readmissions for Acute Myeloid Leukemia Patients Receiving Consolidation Cytarabine Based Therapies

Long-Term Experience with Large Granular Lymphocytic Leukemia Evolving after Solid Organ and Hematopoietic Stem Cell Transplantation

Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Flurabine Improves Transplant Outcomes in Older MDS Patients

Targeted Treatment and Survival Following Relapse after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia and MDS in the Contemporary Era

Interactions between Donor Activating Killer Immunoglobulin-like Receptors (KIRs) and Somatic Mutations and Their Association with Outcomes after Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia (AML)

Outcomes and Factors Impacting Use of Axicabtagene Ciloleucel in Refractory and Relapsed Large B-Cell Lymphoma: An Intent-to-Treat Analysis

A Phase I Trial of Venetoclax in Combination with BEAM Conditioning Chemotherapy (V-BEAM) with Autologous Stem Cell Transplantation in Non-Hodgkin Lymphoma

Pattern of Somatic Mutation Changes from Diagnosis to Relapse Following Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Psychosocial Evaluation in Allogeneic Hematopoietic Cell Transplantation Recipients (Allo HCT): Psychosocial Assessment of Candidates for Transplant (PACT) As a Tool to Identify High-Risk Patients and Its Association with Transplant Outcomes

Tyrosine Kinase Inhibitors with or without Donor Lymphocyte Infusion Continue to Provide Long-Term Survival after Relapse of Chronic Myeloid Leukemia Following Hematopoietic Cell Transplantation

Pharmacist Interventions on Outpatient Leukemia Patients Improve Safety

Survival Advantage to Allogeneic Transplant in Patients with Myelofibrosis with Intermediate-1 or Higher DIPSS Score

Risk of Venous Thromboembolism in Acute Leukemias: A Meta-Analysis

Adolescent and Young Adult (AYA) Hematopoietic Cell Transplantation (HCT) Recipients Have Similar Quality of Life (QoL) Compared to Older Adults in the First Year Post-Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only